Imagine writing a letter of life-and-death importance and trying to mail it only to discover that you have the wrong address, the wrong envelope and no way to buy a stamp. Robert Langer of the ...
A new strategy for engineering protein fusions -- to make specific cell-targeted drugs without side effects -- could enable a safer, more potent class of protein drugs. A team of researchers has ...
UTIs are among the most common bacterial infections worldwide, but inappropriate use and overuse of antibiotics is driving ...
SAN BRUNO, Calif.--(BUSINESS WIRE)--Numerate, Inc., a biotechnology company with a proprietary drug design capability, announced today that it has completed the integration of Pharmix Corporation’s ...
AMES, Iowa – Laboratory video tells the story: tiny, parasitic worms swimming freely in a nutrient solution are active and mobile; expose the same kind of worms to a mixture of four drugs optimized by ...
SAN DIEGO--(BUSINESS WIRE)--Ablexis, LLC (“Ablexis”), a biopharmaceutical company focused on licensing its AlivaMab ® Mouse technology for antibody drug discovery, and AlivaMab Discovery Services, LLC ...
Fail fast, fail cheap is a common clich in drug development. Studies project that anywhere from 4060% of potential drugs candidates fail in development due to absorption, distribution, metabolism, ...
(BOSTON) - A new strategy for engineering protein fusions -- to make specific cell-targeted drugs without side effects -- could enable a safer, more potent class of protein drugs. A team at the Wyss ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback